2020
Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms
Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, Hermes G, Fox HC. Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms. American Journal Of Psychiatry 2020, 178: 447-458. PMID: 33207935, PMCID: PMC8119326, DOI: 10.1176/appi.ajp.2020.20050609.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-1 Receptor AntagonistsAdultAlcohol AbstinenceAlcoholismAnxietyCentral Nervous System DepressantsCounselingCravingDepressionDouble-Blind MethodEthanolFemaleHumansMaleMiddle AgedPrazosinProof of Concept StudySelf-Help GroupsSleep Wake DisordersSubstance Withdrawal SyndromeTreatment OutcomeConceptsAlcohol withdrawal symptomsHeavy drinking daysAlcohol use disorderDrinks/dayWithdrawal symptomsDrinking daysSecondary outcomesPrazosin efficacyAlcohol cravingSelf-reported drinking daysTreatment of AUDEfficacy of prazosinWithdrawal symptom scoresPoor treatment outcomesGlobal disease burdenCurrent alcohol dependencePrimary outcomeTreat analysisAlcohol use outcomesAlcohol intakeSymptom scoresWeek 12Prognostic indicatorDisease burdenSleep disturbancesAssociation of Prefrontal-Striatal Functional Pathology With Alcohol Abstinence Days at Treatment Initiation and Heavy Drinking After Treatment Initiation
Blaine SK, Wemm S, Fogelman N, Lacadie C, Seo D, Scheinost D, Sinha R. Association of Prefrontal-Striatal Functional Pathology With Alcohol Abstinence Days at Treatment Initiation and Heavy Drinking After Treatment Initiation. American Journal Of Psychiatry 2020, 177: 1048-1059. PMID: 32854534, PMCID: PMC7606814, DOI: 10.1176/appi.ajp.2020.19070703.Peer-Reviewed Original ResearchConceptsAlcohol use disorderTreatment initiationAlcohol abstinenceHeavy drinkingFunctional MRIEarly treatment outcomesEarly treatment phaseHealthy control subjectsEarly outpatient treatmentNumber of daysStress imagesDrinking outcomesChronic alcohol abuseHeavy drinking daysSignificant hyperreactivityControl subjectsOutpatient treatmentStriatal dysfunctionEarly treatmentTreatment outcomesBrain stressFunctional pathologyProspective assessmentTreatment phaseAlcohol abuse
2018
Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial
Miranda R, Treloar Padovano H, Gray JC, Wemm SE, Blanchard A. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial. Addictive Behaviors 2018, 83: 72-78. PMID: 29395188, PMCID: PMC5964002, DOI: 10.1016/j.addbeh.2018.01.009.Peer-Reviewed Original Research